Charles Williams Flexner

Professor

1976 …2018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 9 Similar Profiles
HIV Medicine & Life Sciences
HIV-1 Medicine & Life Sciences
HIV Infections Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Ritonavir Medicine & Life Sciences
efavirenz Medicine & Life Sciences
Anti-HIV Agents Medicine & Life Sciences
Drug Interactions Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1976 2018

Antiretroviral implants for treatment and prevention of HIV infection

Flexner, C. W., Jul 1 2018, In : Current Opinion in HIV and AIDS. 13, 4, p. 374-380 7 p.

Research output: Contribution to journalReview article

HIV Infections
Drug Implants
Technology
Nevirapine
Protective Agents

Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine

Ippolito, M., Jacobson, J. M., Lederman, M. M., Winterberg, M., Tarning, J., Shapiro, T. A. & Flexner, C. W., Oct 30 2018, In : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 67, 10, p. 1617-1620 4 p.

Research output: Contribution to journalArticle

Chloroquine
efavirenz
Therapeutics
Protease Inhibitors
Clinical Trials

Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges

Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., Nuermberger, E., Kim, P., Barry, C. E., Owen, A., Hazuda, D. & Flexner, C. W., Feb 1 2018, In : International Journal of Tuberculosis and Lung Disease. 22, 2, p. 125-132 8 p.

Research output: Contribution to journalReview article

Tuberculosis
Infection
HIV
Drug Compounding
Virus Diseases

Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study

Rajoli, R. K. R., Podany, A. T., Moss, D. M., Swindells, S., Flexner, C. W., Owen, A. & Siccardi, M., Aug 1 2018, In : International Journal of Tuberculosis and Lung Disease. 22, 8, p. 937-944 8 p.

Research output: Contribution to journalArticle

rifapentine
bedaquiline
Tuberculosis
Pharmacokinetics
Isoniazid

The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: What are the issues?

Vitoria, M., Hill, A., Ford, N., Doherty, M. C., Clayden, P., Venter, F., Ripin, D., Flexner, C. W. & Domanico, P. L., Jan 1 2018, In : AIDS. 32, 12, p. 1551-1561 11 p.

Research output: Contribution to journalArticle

Tenofovir
efavirenz
Lamivudine
Zidovudine
Drug Resistance